Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
03 Octobre 2024 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: October 03, 2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC
CHAIR SUCCESSION PLAN
Richmond, VA, and Slough, UK, October 3, 2024 - Indivior
PLC (Nasdaq/LSE:
INDV) today announces that Graham Hetherington has informed the
Board of his intention to retire as Chair and from the Board at the
end of 2024 for personal reasons. Graham has been a member of the
Board for five years, including four years as Chair of the
Board.
The Nomination Committee, led by the Senior Independent Director,
Juliet Thompson, has commenced a comprehensive search process to
identify Graham's successor.
The Board would like
to express its sincere thanks to Graham for his significant
contribution to Indivior since joining the Board in
2019.
Graham Hetherington commented:
"It has been a privilege to serve as Chair of Indivior, working
closely with an outstanding Board and highly dedicated management
team who have an unwavering commitment to develop life-transforming
treatments for patients suffering from substance use disorders,
serious mental illness and overdose."
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
+1 804-263-3978 or timothy.owens@indivior.com
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD), overdose and serious mental illnesses. Our vision
is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD. Headquartered
in the United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in
over 30 countries worldwide. Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Indivior (NASDAQ:INDV)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Indivior (NASDAQ:INDV)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
